购物车
  • 全部删除
  • TargetMol
    您的购物车当前为空

OSI-027

Rating icon 很棒
产品编号 T6319Cas号 936890-98-1
别名 OSI027, ASP4786

OSI-027 (ASP4786) 是一种选择性、可口服和 ATP 竞争性的mTOR 激酶活性抑制剂,IC50为 4 nM。它抑制mTORC1和mTORC2,IC50分别为 22 nM 和 65 nM。

OSI-027
TargetMol

为众多的药物研发团队赋能,

让新药发现更简单!

OSI-027

Rating icon 很棒
产品编号 T6319 别名 OSI027, ASP4786Cas号 936890-98-1

OSI-027 (ASP4786) 是一种选择性、可口服和 ATP 竞争性的mTOR 激酶活性抑制剂,IC50为 4 nM。它抑制mTORC1和mTORC2,IC50分别为 22 nM 和 65 nM。

规格价格库存数量
1 mg¥ 267现货
5 mg¥ 693现货
10 mg¥ 1,330现货
25 mg¥ 2,370现货
50 mg¥ 3,680现货
100 mg¥ 5,260现货
1 mL x 10 mM (in DMSO)¥ 762现货
大包装 & 定制
加入购物车
实验操作小课堂
查看更多

"OSI-027"的相关化合物库

选择批次:
纯度:≥95%
联系我们获取更多批次信息
TargetMol 的所有产品仅用作科学研究或药证申报,不能被用于人体,我们不向个人提供产品和服务。请您遵守承诺用途,不得违反法律法规规定用于任何其他用途。

产品介绍

生物活性
产品描述
OSI-027 (ASP4786) is a selective and potent dual inhibitor of mTORC1 and mTORC2 with IC50 of 22 nM and 65 nM, and more than 100-fold selectivity observed for mTOR than PI3Kα, PI3Kβ, PI3Kγ or DNA-PK. Phase 1.
靶点活性
mTORC1:22 nM, mTORC2:65 nM
体外活性
OSI-027 在对mTORC1和mTORC2的选择性及ATP竞争抑制活性上,分别表现出22 nM和65 nM的IC50值。此外,OSI-027以1 μM的IC50,在基于细胞的实验中抑制了mTOR信号通路中的phospho-4E-BP1。[1] OSI-027对几种急性髓系/巨核细胞系列白血病细胞株展现出剂量依赖性的抗增殖活性,包括U937、KG-1、KBM-3B、ML-1、HL-60和MEG-01细胞。[2] 最近的研究表明,OSI-027通过抑制mTORC1/2有效地抑制了Akt(S473)的磷酸化和乳腺癌细胞的增殖。[3]
体内活性
在GEO结直肠癌异种移植模型中,OSI-027(65 mg/kg)抑制了包括4E-BP1、Akt和S6磷酸化在内的mTORC1和mTORC2效应物。此外,通过OSI-027共同抑制mTORC1和mTORC2,较单独使用雷帕霉素抑制mTORC1更有效地抑制肿瘤生长。[1]
激酶实验
Biochemical assays: mTORC1 and mTORC2 inhibition is assayed using native enzyme complex immunoprecipitated from HeLa lysates at 1 mM ATP. To prepare whole cell lysates from HeLa cells, 25 g cell pellet is lysed in 60 mL of ice-cold buffer A [40 mM HEPES (pH 7.5), 120 mM NaCl, 1 mM EDTA, 10 mM sodium pyrophosphate, 10 mM glycerophosphate, 50 mM NaF, 0.5 mM orthovanadate, and EDTA-free protease inhibitors containing 0.3% CHAPS] for 30 minutes on a magnetic stirrer in a cold room. After clearing of the lysates by centrifugation at 13,000 g for 10 minutes, Protein G-coated 384-well plates are incubated with 0.25 μg of mTOR antibody in 15 μL of buffer A for 1 hour at 4 °C. To each well, 40 μg of HeLa cell lysate in 15 μL of buffer A is added and incubated overnight at 4 °C to immunoprecipitate mTOR complexes. Plates are washed 3 times with buffer A and twice with immunoprecipitation wash buffer [Buffer B: 50 mM HEPES (pH 7.5) and 150 mM NaCl]. OSI-027 is added at 10 μM concentration to each well and DMSO is added to the control wells. The reaction is started by adding 150 ng of His-tagged 4E-BP1 as a substrate in the presence or absence of 100 μM ATP to each well in 25 μL of freshly prepared kinase buffer [Buffer C: 20 mM HEPES (pH 7.5), 10 mM MgCl2, 4 mM MnCl2, 10 mM β-mercaptoethanol, and 200 μM vanadate] and incubated at room temperature (RT) for 30 minutes. The reaction is stopped by transferring 25 μL of reaction mixture from each well to corresponding wells of fresh Ni-chelate-coated plates and incubated overnight at 4 °C followed by 2 hours at 37 °C. To detect phosphorylation of 4E-BP1, the plates are washed once with TBST (Tris-buffered saline containing 0.1% Tween-20) containing 5% skim milk powder. To each well, 25 μL of 1:1,000 diluted phospho-4E-BP1 antibodies in TBST containing 5% skim milk are added and incubated for 1 hour at RT.The plates are washed once with TBST and then 25 μL of anti-rabbit HRP (diluted 1:10,000) in TBST containing 5% skim milk is added. The plates are incubated for 1 hour at RT and washed 5 times with TBST. For detection of phospho-4E-BP1, 25 μL of chemiluminescent reagents A+B is added and chemiluminescence is measured using an Analyst plate reader.
细胞实验
Inhibition of proliferation is measured using the Cell Titer Glo Assay , as noted in figure legends. To generate dose–response curves, cell lines are seeded at a density of 5,000 cells per well in a 96-well plate. After 24 hours of plating, cells are dosed with varying concentrations of either OSI-027 or rapamycin. The signal for Cell Titer Glo Assay is determined 72 hours after dosing and normalized to that of vehicle-treated controls. Inhibition of proliferation, relative to vehicle-treated controls, is expressed as a fraction of 1 and graphed using PRISM software. (Only for Reference)
别名OSI027, ASP4786
化学信息
分子量406.44
分子式C21H22N6O3
CAS No.936890-98-1
SmilesCOc1cccc2=C\C(N=c12)=c1/nc(C2CCC(CC2)C(O)=O)n2NC=NC(N)=c12
密度1.59 g/cm3
储存&溶解度
存储Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice.
溶解度信息
DMSO: 15 mg/mL (36.9 mM)
H2O: < 1 mg/mL (insoluble or slightly soluble)
Ethanol: < 1 mg/mL (insoluble or slightly soluble)
溶液配制表
1mg5mg10mg50mg
1 mM2.4604 mL12.3019 mL24.6039 mL123.0194 mL
5 mM0.4921 mL2.4604 mL4.9208 mL24.6039 mL
10 mM0.2460 mL1.2302 mL2.4604 mL12.3019 mL
20 mM0.1230 mL0.6151 mL1.2302 mL6.1510 mL

计算器

  • 摩尔浓度 计算器
  • 稀释 计算器
  • 配液 计算器
  • 分子量 计算器

体内实验配液计算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:
TargetMol | Animal experiments比如您的给药剂量是 10 mg/kg ,每只动物体重 20 g ,给药体积 100 μLTargetMol | Animal experiments 一共给药动物 10 只 ,您使用的配方为 5% TargetMol | reagent DMSO+ 30%PEG300+ 5%Tween 80 + 60% ddH2O. 那么您的工作液浓度为 2 mg/mL
母液配置方法: 2 mg 药物溶于 50 μLDMSOTargetMol | reagent ( 母液浓度为 40 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:50μLDMSOTargetMol | reagent 母液,添加 300 μLPEG300TargetMol | reagent 混匀澄清,再加 50μLTween 80, 混匀澄清,再加 600μLddH2OTargetMol | reagent 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

1 请输入动物实验的基本信息
mg/kg
g
μL
2 请输入动物体内配方组成,不同的产品配方组成不同,如有配方需求,可先联系我们提供正确的体内配方。
% DMSO
%
%Tween 80
%ddH2O

剂量转换

对于不同动物的给药剂量换算,您也可以参考 更多

关键词

评论列表

4个月前
5.0
Rating icon 很棒

评论内容

Related Tags: buy OSI-027 | purchase OSI-027 | OSI-027 cost | order OSI-027 | OSI-027 chemical structure | OSI-027 in vivo | OSI-027 in vitro | OSI-027 formula | OSI-027 molecular weight